Analyst Reco. ResMed Inc. Australian S.E.

Equities

RMD

AU000000RMD6

Market Closed - Australian S.E. Other stock markets 02:10:36 2024-05-15 am EDT			5-day change	1st Jan Change
32.7 ^AUD	-0.24%		+0.03%	+28.54%

May. 10	Resmed Insider Sold Shares Worth $2,747,810, According to a Recent SEC Filing	MT
May. 09	Resmed Insider Sold Shares Worth $3,178,815, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Resmed Insider Sold Shares Worth $2,747,810, According to a Recent SEC Filing	May. 10	MT
Resmed Insider Sold Shares Worth $3,178,815, According to a Recent SEC Filing	May. 09	MT
KeyBanc Adjusts Price Target on ResMed to $238 From $227	Apr. 26	MT
Jefferies Adjusts Price Target on ResMed to $180 From $164	Apr. 26	MT
Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating	Apr. 26	MT
JPMorgan Adjusts Price Target on ResMed to $225 From $198	Apr. 26	MT
Mizuho Adjusts Price Target on ResMed to $220 From $215	Apr. 26	MT
Needham Adjusts Price Target on ResMed to $236 From $224	Apr. 26	MT
Morgan Stanley Adjusts Price Target on ResMed to $219 From $207	Apr. 26	MT
RBC Adjusts Price Target on ResMed to $200 From $187	Apr. 26	MT
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating	Apr. 01	MT
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight	Mar. 05	MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31	Mar. 04	MT
Powell, the paper tiger	Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...	Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating	Jan. 30	MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating	Jan. 30	MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating	Jan. 25	MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating	Jan. 25	MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating	Jan. 25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ResMed, Inc. continues to make headway in the sleep market

December 11, 2023 at 05:55 am EST